Loading
Life sciences · Journal article
Acs Applied Nano Materials · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Combination of 131I radioiodine therapy and photodynamic therapy represents a potential strategy for improving the treatment of differentiated thyroid cancer. Herein, we developed a silver single-atom carbon nitride photosensitizer (Ag1−N2), which is activated by the in situ light source of 131I Cherenkov radiation, for effective photodynamic therapy in differentiated thyroid cancer. Atomically dispersed Ag formed well-defined Ag−N2 coordination sites on g-C3N4, which adjust the energy band structure, optimizes *OH desorption, and inhibits its excessive reduction, thereby promoting the one-electron reduction of H2O2 into •OH and cascading reactive oxygen species amplification. Additionally, Ag1−N2 showed preliminary tolerability. In combination with Na131I, Ag1−N2 enhanced intracellular ROS generation, reduced TPC-1 cell viability by approximately 80%, and produced greater tumor-growth inhibition than either monotherapy. This study presents an in situ Cherenkov-activated silver single-atom nanoplatform that offers a promising combination-therapy strategy for differentiated thyroid cancer.